sglt2 inhibitors and glp-1 receptor agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application SGLT2 Inhibitors and GLP-1 Receptor
Description
AK and SAA provided administrative, technical and material support
Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use
These findings may also help explain why the risk of pancreatitis appears to be of greater magnitude during the first 6 months of treatment
Maternal body mass index, gestational weight gain, and the risk of overweight and obesity across childhood: an individual participant data meta-analysis
Environmental factorssuch as unhealthy dietary patterns, limited physical activity, and inadequate sleepfurther promote weight gain
Combining EXE with PIO also suppressed the significant change in body weight induced by PIO compared to weight gain found after its administration
